FGFR2 aberrations are estimated to be present in approximately 15–20% of cases of intrahepatic cholangiocarcinoma (iCCA), which has led to the development and testing of drugs that target FGFR2 [20,21]. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.